HM
HealthCor Management Portfolio holdings
AUM
$109M
This Quarter Return
+23.75%
1 Year Return
+11.46%
3 Year Return
+50.01%
5 Year Return
+144.68%
10 Year Return
–
AUM
$109M
AUM Growth
+$109M
(-86%)
Cap. Flow
-$719M
Cap. Flow
% of AUM
-658.8%
Top 10 Holdings %
Top 10 Hldgs %
91.26%
Holding
65
New
6
Increased
2
Reduced
11
Closed
43
Top Buys
| 1 |
DexCom
DXCM
|
$7.69M |
| 2 |
Acrivon Therapeutics
ACRV
|
$3.27M |
| 3 |
CONMED
CNMD
|
$2.44M |
| 4 |
Intuitive Surgical
ISRG
|
$1.53M |
| 5 |
Penumbra
PEN
|
$1.11M |
Top Sells
| 1 |
AbbVie
ABBV
|
$41.6M |
| 2 |
Agilent Technologies
A
|
$41.1M |
| 3 |
BioMarin Pharmaceuticals
BMRN
|
$40.5M |
| 4 |
Boston Scientific
BSX
|
$37.1M |
| 5 |
Eli Lilly
LLY
|
$33.4M |
Sector Composition
| 1 | Healthcare | 99.98% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Danaher
DHR
$143B
| – | – |
-117,800
| Closed | -$30.4M |
|
52
CVS Health
CVS
$93B
| – | – |
-131,150
| Closed | -$12.5M |
|
53
Cencora
COR
$57.2B
| – | – |
-239,150
| Closed | -$32.4M |
|
54
Centene
CNC
$14.8B
| – | – |
-300,970
| Closed | -$23.4M |
|
55
Cigna
CI
$80.2B
| – | – |
-76,910
| Closed | -$21.3M |
|
|
56
Boston Scientific
BSX
$159B
| – | – |
-958,600
| Closed | -$37.1M |
|
57
Bristol-Myers Squibb
BMY
$96.7B
| – | – |
-223,150
| Closed | -$15.9M |
|
|
BLUE
58
DELISTED
bluebird bio
BLUE
| – | – |
-455,000
| Closed | -$2.88M |
|
59
Biogen
BIIB
$20.8B
| – | – |
-69,950
| Closed | -$18.7M |
|
60
Becton Dickinson
BDX
$54.3B
| – | – |
-62,930
| Closed | -$14M |
|
61
Amgen
AMGN
$153B
| – | – |
-75,370
| Closed | -$17M |
|
|
AFMD
62
DELISTED
Affimed
AFMD
| – | – |
-1,721,925
| Closed | -$3.55M |
|
63
Abbott
ABT
$230B
| – | – |
-98,970
| Closed | -$9.58M |
|
|
64
AbbVie
ABBV
$374B
| – | – |
-310,250
| Closed | -$41.6M |
|
|
65
Agilent Technologies
A
$35.5B
| – | – |
-338,030
| Closed | -$41.1M |
|